Startup Profile: Kvantify ApS
Kvantify aims to revolutionize drug discovery by leveraging quantum and quantum-inspired algorithms to make the process faster, more accurate, and cost-effective. They seek to solve complex computational problems in drug development and expand applications to other industries like financial services.
Website: https://www.kvantify.com
Industry: Quantum Computing and Drug Discovery
Founded: 2022
Headquarters: Denmark
-
The pharmaceutical industry faces significant challenges with drug discovery being a slow, costly, and complex process. Traditional computational methods struggle with efficiently simulating small molecule dynamics, leading to long development times and high failure rates.
-
Kvantify develops proprietary quantum algorithms, such as Autorank and FAST VQE, combining classical and quantum computing methods to efficiently simulate small molecule dynamics. This accelerates the drug discovery process, reduces costs, and increases the success rate of developing new drugs.
-
Advancements in quantum computing technologies have reached a point where they can provide practical benefits to industries like pharmaceuticals. There's an urgent need for more efficient drug discovery methods, and quantum computing offers a viable solution to meet this demand.
FINANCIALS
Kvantify recently raised β¬7 million in a seed funding round, securing support from a consortium of reputable investors. This funding provides a strong financial runway, enabling them to sustain operations for over 24 months. The investment will be used to drive product development, expand their team, and launch their SaaS platform, further advancing their quantum computing solutions.
MARKET SIZE
While specific figures are not provided, the pharmaceutical industry invests billions annually in drug discovery and development. The market for computational drug discovery tools is significant and growing, as companies seek ways to reduce costs and accelerate time-to-market.
TEAM
Kvantify's team is led by co-founders Allan GrΓΈnlund, an expert in quantum computing algorithms, Nikolaj Thomas Zinner, a specialist in quantum physics and computational methods, and Hans Henrik Knudsen, who brings extensive experience in drug discovery and development. The company has grown to a team of over 50 experts, including 35 PhDs and 12 professors, combining deep expertise in quantum computing and drug discovery to drive innovation in the field
-
Kvantify works with customer projects and pilots to tailor quantum computing solutions for clients, with an initial focus on drug discovery. Their proprietary algorithms, including Autorank and FAST VQE, integrate classical and quantum computing methods to efficiently simulate small molecule dynamics. In 2024, they launched a scalable SaaS platform, providing broader access to their quantum solutions. They also have ongoing research initiatives to advance their technology into new applications, such as finance, where they apply their computational expertise to solving complex financial problems.
-
Currently, Kvantify generates revenue through customer projects and pilots with enterprise clients. They plan to transition to a SaaS model with the upcoming platform launch, enabling scalable and recurring revenue streams. Revenue sources include:
Service fees from customer projects.
Subscription fees from the SaaS platform.
Research grants and partnerships.
-
Competitors include companies like Zapata Computing, ProteinQure, and Qulab, which are also developing quantum computing solutions for drug discovery. Kvantify differentiates itself through proprietary algorithms that outperform current techniques, an exceptional team of experts, early revenue generation from customer projects, and exploration of applications beyond pharmaceuticals.